Seek Returns

GILD vs. RGEN: Gilead Sciences vs. Repligen Stock Comparison

How do Gilead Sciences (GILD) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Gilead Sciences (GILD) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.

Company profile comparison for Gilead Sciences (GILD) and Repligen (RGEN)
Profile ItemGILDRGEN
NameGilead Sciences Inc.Repligen Corporation
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization207.00 billion USD11.09 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJanuary 22, 1992April 29, 1986
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

GILD
RGEN
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Gilead Sciences (GILD) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Gilead Sciences (GILD) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
Total Return (1Y)45.69%23.28%
Total Return (3Y, Annualized)35.30%6.20%
Total Return (5Y, Annualized)25.00%-8.41%

Risk Profile

Drawdown History

GILD
RGEN
GSPC
Loading price history…
Gilead Sciences (GILD) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Gilead Sciences (GILD) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
Volatility (1Y, Annualized)27.57%46.73%
Beta (5Y)0.361.11
Max Drawdown (5Y)-26.59%-64.67%
Avg. Volume (3M)5.98M1.18M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
GILD and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
Sharpe Ratio (1Y)1.500.41
Sortino Ratio (1Y)2.480.60

Profitability

ROE (TTM)

Both Gilead Sciences (GILD) at -22.45% and Repligen (RGEN) at -0.57% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Gilead Sciences (GILD) at -12.46% and Repligen (RGEN) at -1.47% report negative net margin values, usually indicating net losses over the period.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Gilead Sciences (GILD) at 42.43% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
ROE (TTM)-22.45%-0.57%
ROA (TTM)13.47%1.40%
Net Margin (TTM)-12.46%-1.47%
Operating Margin (TTM)42.43%6.19%
Gross Margin (TTM)79.95%53.77%

Growth

Revenue Growth

Both Gilead Sciences (GILD) at 2.39% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Gilead Sciences (GILD) reports EPS growth of 1,684.21%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
Revenue Growth (YoY)2.39%16.36%
Revenue Growth (3Y CAGR)2.57%-2.70%
EPS Growth (YoY)1,684.21%--
EPS Growth (3Y CAGR)23.04%-35.73%

Financial Strength

Current Ratio (MRQ)

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Repligen (RGEN) at 0.33 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
Current Ratio (MRQ)1.389.88
Debt / Equity (MRQ)2.020.33
Net Debt / EBITDA1.25-1.19

Dividends

Dividend Yield (TTM)

Repligen (RGEN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Repligen (RGEN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
Dividend Yield (TTM)1.94%0.00%
Dividend Payout Ratio (TTM)43.46%0.00%

Valuation

P/E Ratio (TTM)

Neither Gilead Sciences (GILD) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Gilead Sciences (GILD) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Gilead Sciences (GILD) and Repligen (RGEN)
MetricGILDRGEN
P/E Ratio (TTM)----
P/S Ratio (TTM)6.6813.77
P/B Ratio (MRQ)15.884.70
Free Cash Flow Yield (TTM)5.16%1.01%